financetom
Business
financetom
/
Business
/
What's Going On With NewGenIvf Shares Thursday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With NewGenIvf Shares Thursday?
Mar 10, 2026 8:15 PM

NewGenIvf Group Limited ( NIVF ) shares are trading higher on Thursday after the company announced it secured $5.2 million in funding in order to drive international expansion, with the potential to secure up to an additional $30.8 million.

What To Know: The more than $5 million in funding will be used to establish a new fertility clinic in Dubai, which will leverage NewGen’s recently acquired Microsort technology. The facility will provide services such as IVF with gender selection, egg donation and surrogacy, serving patients from the UAE, the EU and other countries.

The company expects construction of the facility to begin in the second quarter, with its opening targeted for the fourth quarter this year.

“This strategic funding marks a significant milestone in our global expansion strategy and provides the liquidity we need to drive our long-term growth. The UAE’s progressive regulatory environment for fertility treatments allows us to offer a full suite of services, making it an ideal region for the next step of our expansion efforts,” said Sin Wing Fung Alred, CEO of NewGen.

“By capitalizing on our recently acquired Microsort technology, we plan to establish a strong presence in Dubai, which we hope will serve as a hub to reach patients from a variety of regions. This expansion represents a pivotal step in our commitment to providing world-class fertility solutions to patients around the world.”

NewGenIvf ( NIVF ) shares are trading on higher-than-normal session volume at 76.69 million. The average session volume over the past 100 days for the stock is is 1.20 million, per data from Benzinga Pro.

See Also: Trump’s Tariffs Prompt China To Vow ‘Countermeasures’: Experts See Retaliation Likely

NIVF Price Action: At the time of writing, NewGenIvf ( NIVF ) shares are trading 29.1% higher at $0.76, according to data from Benzinga Pro.

Image: via Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Norway wealth fund to vote against Musk's $56 billion Tesla pay package
Norway wealth fund to vote against Musk's $56 billion Tesla pay package
Jun 10, 2024
OSLO (Reuters) -Norway's $1.7 trillion sovereign wealth fund said on Saturday it will vote against ratifying Tesla CEO Elon Musk's $56 billion pay package, which is up for a shareholder vote next week, after a Delaware judge invalidated it earlier this year. The fund is Tesla's eighth-biggest shareholder, according to LSEG data. Musk's pay, the largest for a chief executive...
Newcore Gold Files Technical Report for Updated Preliminary Economic Assessment for Enchi Gold Project in Ghana
Newcore Gold Files Technical Report for Updated Preliminary Economic Assessment for Enchi Gold Project in Ghana
Jun 10, 2024
06:46 AM EDT, 06/10/2024 (MT Newswires) -- Newcore Gold ( NCAUF ) said on Friday that it filed the technical report for the independent, updated preliminary economic assessment for the company's 100%-owned Enchi Gold Project in Ghana. The company reported an average annual gold production of 121,839 ounces and peak gold production in year six of 155,188 ounces. Also, the...
Oculis Sees Favorable Topline Results in Study of Potential Dye-Eye Disease Treatment
Oculis Sees Favorable Topline Results in Study of Potential Dye-Eye Disease Treatment
Jun 10, 2024
06:44 AM EDT, 06/10/2024 (MT Newswires) -- Oculis Holding (OCS) said Monday it had detected favorable topline results from a phase 2b trial of licaminlimab for the treatment of patients with dry-eye disease. The 122-patient study showed treatment effects favoring licaminlimab in multiple sign endpoints accepted by the US Food and Drug Administration. ...
Moderna COVID/flu combo vaccine superior to separate shots in trial
Moderna COVID/flu combo vaccine superior to separate shots in trial
Jun 10, 2024
June 10 (Reuters) - Moderna ( MRNA ) said on Monday its combination vaccine to protect against both COVID-19 and influenza generated a stronger immune response in adults aged 50 and over when compared to separate shots against the viruses in a late-stage trial. In the study, the combination using messenger RNA technology generated greater antibodies than currently marketed traditional...
Copyright 2023-2026 - www.financetom.com All Rights Reserved